CA Patent

CA2887243C — Methods of treating cancer

Assigned to Epizyme Inc · Expires 2024-04-09 · 2y expired

What this patent protects

EZH2 inhibitor, and its use, for treating a cancer selected from the group consisting of malignant rhabdoid tumor and epitheloid sarcoma, wherein, the EZH2 inhibitor is: (A) or a pharmaceutically acceptable salt thereof.

USPTO Abstract

EZH2 inhibitor, and its use, for treating a cancer selected from the group consisting of malignant rhabdoid tumor and epitheloid sarcoma, wherein, the EZH2 inhibitor is: (A) or a pharmaceutically acceptable salt thereof.

Drugs covered by this patent

tazemetostat-hydrobromide (TAZEMETOSTAT HYDROBROMIDE)

Patent Metadata

Patent number: CA2887243C
Jurisdiction: CA
Classification: —
Expires: 2024-04-09
Drug substance claim: No
Drug product claim: No
Assignee: Epizyme Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.